Mayo Clinic Robert and Arlene Kogod Center on Aging
Academic
About
The Robert and Arlene Kogod Center on Aging is Mayo Clinic's centre for research on the biology of aging and healthspan. It connects clinicians and scientists across Mayo's campuses in Minnesota, Arizona and Florida, with its administrative office in Rochester. It was established with a founding gift in 2002 and formally opened in 2008. The centre is closely associated with cellular senescence research: in 2011, center scientists showed in Nature that clearing p16Ink4a-positive senescent cells in mice delays age-related disorders. Later work at Mayo led to the discovery of senolytic drugs and to early clinical studies of them. Its six research programmes and three themes aim to link basic mechanisms with clinical application. Current work includes an NIA programme project, led by the centre, on targeting cellular senescence to extend healthspan. Nathan LeBrasseur directs the centre, with Eduardo Chini and João Passos as associate directors.
Rating breakdown
Aggregate 66/100 · rank #5 in the academic & non-profit table full ratings →
Expand a signal to see what contributes to it.
Publications75
- Nathan LeBrasseur — h-index 89 source ↗
- João Passos — h-index 75 source ↗
- Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders (Baker et al., Nature) ↗
- Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (Baker et al., Nature) ↗
- Senolytics improve physical function and increase lifespan in old age (Xu et al., Nature Medicine) ↗
- Targeting cellular senescence prevents age-related bone loss in mice (Farr, Khosla et al., Nature Medicine) ↗
- Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans (Zhu et al., eBioMedicine) ↗
Discovery78
Trials from ClinicalTrials.gov (this org as lead sponsor), matched to aging by their condition or intervention.
- The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (first senolytics, dasatinib + quercetin; Zhu et al., Aging Cell) ↗
- Senescence in Chronic Kidney Disease (senolytic trial, lead sponsor Mayo Clinic), NCT02848131 ↗
- Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM), lead sponsor Mayo Clinic, NCT03430037 ↗
- Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans (PI Sundeep Khosla, Mayo Clinic), NCT04313634 ↗
Fundraising93
Grants of the organisation's listed people, name-matched via NIH RePORTER ↗.
- Nathan LeBrasseur: Project 2 - Cellular Senescence and Skeletal Muscle Aging · USD 601K · National Institute on Aging 5P01AG062413-08
- João Passos: Core D - Senescence Molecular Phenotyping Core (SMPC) · USD 562K · National Institute on Aging 5P01AG062413-08
- Darren Baker: JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP) · USD 492K · National Institute on Aging 3U54AG079779-04S2
- Nathan LeBrasseur: Core A - Administrative and Systems Biology of Aging Core (ASBC) · USD 361K · National Institute on Aging 5P01AG062413-08
- João Passos: Development of machine learning software to quantitatively map telomere induced senescence in tissue sections during aging · USD 200K · National Cancer Institute 3UH3CA268103-04S1
- Darren Baker: Transgenic and Knockout Shared Resource · USD 152K · National Cancer Institute 5P30CA015083-51
Education10
- James Kirkland ARDD speaker 2024;2025;2026 source ↗
- Nathan LeBrasseur ARDD speaker 2025 source ↗
Key outputs
- publication Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders (Baker et al., Nature) ↗ 2011
- publication Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (Baker et al., Nature) ↗ 2016
- discovery The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (first senolytics, dasatinib + quercetin; Zhu et al., Aging Cell) ↗ 2015
- publication Senolytics improve physical function and increase lifespan in old age (Xu et al., Nature Medicine) ↗ 2018
- clinical trial Senescence in Chronic Kidney Disease (senolytic trial, lead sponsor Mayo Clinic), NCT02848131 ↗ 2016
- publication Targeting cellular senescence prevents age-related bone loss in mice (Farr, Khosla et al., Nature Medicine) ↗ 2017
- publication Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans (Zhu et al., eBioMedicine) ↗ 2022
- clinical trial Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM), lead sponsor Mayo Clinic, NCT03430037 ↗ 2018
- clinical trial Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans (PI Sundeep Khosla, Mayo Clinic), NCT04313634 ↗ 2020
Investment & funding
| Date | Type | Amount | Detail | Counterparties |
|---|---|---|---|---|
| 2026 | grant | USD 4M | NIH (NIA) publicly disclosed FY2026 award for P01 AG062413, Targeting Cellular Senescence to Extend Healthspan (NIH RePORTER parent record) | National Institute on Aging |
Key people
Research fields
Links
Sources
- https://www.mayo.edu/research/centers-programs/robert-arlene-kogod-center-aging
- https://www.mayo.edu/research/centers-programs/robert-arlene-kogod-center-aging/about
- https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041
- https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365
- https://www.mayo.edu/research/faculty/baker-darren-j-ph-d-m-s/bio-00027985
- https://reporter.nih.gov/project-details/11301868
- https://clinicaltrials.gov/study/NCT02848131
- https://doi.org/10.1038/nature10600
- https://doi.org/10.1038/nature16932
- https://doi.org/10.1111/acel.12344
- https://doi.org/10.1038/s41591-018-0092-9
- https://www.mayo.edu/research/faculty/khosla-sundeep-m-d/bio-00078126
- https://doi.org/10.1038/nm.4385
- https://doi.org/10.1016/j.ebiom.2022.103912
- https://clinicaltrials.gov/study/NCT03430037
- https://clinicaltrials.gov/study/NCT04313634